1. Clinical & Scientific Overview
Tigecycline (TIP-MED-000533, Reference Code [R-14]) is classified under
Reserve Antimicrobials (WHO AWaRe Reserve) as a Glycylcycline Broad-Spectrum Reserve Antibiotic.
Within the Indian regulatory and compendial framework, it is governed under Schedule H1 Reserve Antibiotic.
Tygacil (Pfizer Ltd), Tigebax (Ranbaxy / Sun Pharma), Tekcyn (Cipla Ltd)
Lyophilised Powder for IV Infusion: 50 mg vial
Statutory Restriction, High-Alert & Dispensing Safeguards
Indian Regulatory & Statutory Control Basis: Schedule H1 Reserve Antibiotic
High-Alert Clinical Risk, Dependence & Narrow Therapeutic Index Warnings: Boxed Warning: Increased all-cause mortality compared to comparator antibiotics in ventilator-associated pneumonia and bacteraemia due to large volume of distribution (>7 L/kg) and low serum Cmax (<0.9 mcg/mL); severe nausea/vomiting, acute pancreatitis, and hepatotoxicity.
Mandatory Dispensing Register & Institutional Custody Protocol: Loading dose 100 mg IV, then 50 mg IV q12h; reduce maintenance dose to 25 mg IV q12h in severe hepatic impairment (Child-Pugh C); never use as monotherapy for bacteraemia or Pseudomonas.
3. Mechanism of Action & Pharmacodynamics
Binds with 5-fold higher affinity than tetracyclines to the 30S ribosomal subunit, blocking aminoacyl-tRNA entry and overcoming ribosomal protection (tetM) and efflux (tetA-E) resistance mechanisms.
4. Therapeutic Indications & Evidence-Supported Uses
- Complicated intra-abdominal infections (cIAI) and complicated skin/soft-tissue infections (cSSTI) caused by MDR organisms (excluding Pseudomonas and Proteus)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Specialist-Supervised Educational Reference Summary: Dosing of Tigecycline must be individualised by a qualified specialist according to clinical indication, organ function, and institutional protocol (Lyophilised Powder for IV Infusion: 50 mg vial).
Administration & Meal Timing: Routes: Intravenous Infusion. Loading dose 100 mg IV, then 50 mg IV q12h; reduce maintenance dose to 25 mg IV q12h in severe hepatic impairment (Child-Pugh C); never use as monotherapy for bacteraemia or Pseudomonas.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Exhibits glycylcycline broad-spectrum reserve antibiotic pharmacokinetic disposition; verify baseline renal and hepatic clearance and check for active or prolonged-half-life metabolites before repeat dosing.
Hepatic Phase I (CYP450) and/or Phase II conjugation or specific non-renal clearance as detailed in clinical warnings.
Verify eGFR / CrCl before initiation; see specific metabolite and renal clearance notes above.
Assess baseline Child-Pugh status and hepatic transaminases prior to therapy.
7. Contraindications, Precautions & High-Risk Warnings
- Known severe hypersensitivity to Tigecycline or formulation excipients
- Unsupervised outpatient self-administration or dispensing without mandatory statutory prescription verification
- Specific clinical contraindications detailed under High-Alert Warnings & Statutory Restrictions
Key Clinical Precautions: Boxed Warning: Increased all-cause mortality compared to comparator antibiotics in ventilator-associated pneumonia and bacteraemia due to large volume of distribution (>7 L/kg) and low serum Cmax (<0.9 mcg/mL); severe nausea/vomiting, acute pancreatitis, and hepatotoxicity.
8. Adverse Effects Profile
- Boxed Warning: Increased all-cause mortality compared to comparator antibiotics in ventilator-associated pneumonia and bacteraemia due to large volume of distribution (>7 L/kg) and low serum Cmax (<0.9 mcg/mL); severe nausea/vomiting, acute pancreatitis, and hepatotoxicity.
- Dose-dependent target-organ pharmacodynamic effects requiring clinical observation
- Boxed Warning: Increased all-cause mortality compared to comparator antibiotics in ventilator-associated pneumonia and bacteraemia due to large volume of distribution (>7 L/kg) and low serum Cmax (<0.9 mcg/mL); severe nausea/vomiting, acute pancreatitis, and hepatotoxicity.
- High-alert toxicity, dependence/diversion risk, or severe organ-specific adverse events if administered outside protocol
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Boxed Warning: Increased all-cause mortality compared to comparator antibiotics in ventilator-associated pneumonia and bacteraemia due to large volume of distribution (>7 L/kg) and low serum Cmax (<0.9 mcg/mL); severe nausea/vomiting, acute pancreatitis, and hepatotoxicity.
- Review all concomitant CNS depressants, QTc-prolonging agents, nephrotoxins, or CYP450 modulators prior to dispensing.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Loading dose 100 mg IV, then 50 mg IV q12h; reduce maintenance dose to 25 mg IV q12h in severe hepatic impairment (Child-Pugh C); never use as monotherapy for bacteraemia or Pseudomonas.
Pharmacist Patient Counselling Points:
- Loading dose 100 mg IV, then 50 mg IV q12h; reduce maintenance dose to 25 mg IV q12h in severe hepatic impairment (Child-Pugh C); never use as monotherapy for bacteraemia or Pseudomonas.
- Must be used strictly under direct medical supervision; never share prescription medicines or alter the prescribed dose.
Storage, Stability & Dispensing Safeguards: Loading dose 100 mg IV, then 50 mg IV q12h; reduce maintenance dose to 25 mg IV q12h in severe hepatic impairment (Child-Pugh C); never use as monotherapy for bacteraemia or Pseudomonas.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Drugs and Cosmetics Act, 1940 & Rules, 1945 (Schedule H / H1 / X); NDPS Act, 1985 & Essential Narcotic Drugs (END) Notification; Indian Pharmacopoeia (IP) & National Formulary of India (NFI).
Official Verification Portals: CDSCO — Drugs & Cosmetics Act and Rules (Schedules H, H1, X) • Department of Revenue — Narcotic Drugs and Psychotropic Substances (NDPS) Act • Indian Pharmacopoeia Commission (IPC) — National Formulary of India
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [R-15] Ceftazidime + Avibactam — 3rd-Generation Cephalosporin + Non-Beta-Lactam Diazabicyclooctane
- [R-16] Meropenem + Vaborbactam — Carbapenem + Cyclic Boronic Acid Beta-Lactamase Inhibitor
- [R-17] Cefiderocol — Siderophore Cephalosporin ('Trojan Horse' Reserve Antibiotic)
- [R-18] Tedizolid Phosphate — Second-Generation Oxazolidinone Reserve Antibiotic
